A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
Chang KC, Tseng PL, Wu YY, Hung HC, Huang CM, Lu SN, Wang JH, Lee CM, Chen CH, Tsai MC, Yen YH, Lin MT, Wu CK, Huang CC, Chen HH, Hu TH.
Chang KC, et al. Among authors: wu yy, wu ck.
Clin Gastroenterol Hepatol. 2015 May;13(5):1017-24. doi: 10.1016/j.cgh.2014.10.035. Epub 2014 Nov 13.
Clin Gastroenterol Hepatol. 2015.
PMID: 25460552